US6835557B1
(en)
*
|
1980-01-08 |
2004-12-28 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
|
DE3176011D1
(en)
*
|
1980-06-12 |
1987-04-23 |
Japan Found Cancer |
Plasmid
|
US6610830B1
(en)
*
|
1980-07-01 |
2003-08-26 |
Hoffman-La Roche Inc. |
Microbial production of mature human leukocyte interferons
|
US4810645A
(en)
*
|
1981-08-14 |
1989-03-07 |
Hoffmann-La Roche Inc. |
Microbial production of mature human leukocyte interferon K and L
|
IE54592B1
(en)
*
|
1982-03-08 |
1989-12-06 |
Genentech Inc |
Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
|
US5399684A
(en)
*
|
1982-05-20 |
1995-03-21 |
Washington Research Foundation |
DNA sequences expressing mammalian alpha-1-antitrypsin
|
DE3220116A1
(de)
*
|
1982-05-28 |
1983-12-01 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
|
JPS60222500A
(ja)
*
|
1983-12-19 |
1985-11-07 |
シエリング・コ−ポレ−シヨン |
新規ハイブリツドインタ−フエロン
|
US5248666A
(en)
*
|
1984-03-23 |
1993-09-28 |
Oncogen |
Methods for inhibiting neoplastic cell proliferation using platelet factor 4
|
US4710465A
(en)
*
|
1984-04-19 |
1987-12-01 |
Yale University |
Junction-fragment DNA probes and probe clusters
|
SU1364343A1
(ru)
*
|
1984-07-13 |
1988-01-07 |
Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов |
Способ получени человеческого лейкоцитарного интерферона альфа-2
|
US5871956A
(en)
*
|
1984-12-06 |
1999-02-16 |
Amgen Inc. |
Recombinant methods for production of serine inhibitors and DNA sequences useful for same
|
US6291662B1
(en)
|
1984-12-05 |
2001-09-18 |
Amgen Inc. |
Recombinant methods for production of serine protease inhibitors and DNA sequences
|
US5900400A
(en)
*
|
1984-12-06 |
1999-05-04 |
Amgen Inc. |
Serine protease inhibitor analogs
|
US6132990A
(en)
*
|
1984-12-06 |
2000-10-17 |
Amgen Boulder Inc. |
Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
|
US5081019A
(en)
*
|
1985-01-10 |
1992-01-14 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides
|
US4950646A
(en)
*
|
1985-01-10 |
1990-08-21 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides
|
US4874743A
(en)
*
|
1985-01-10 |
1989-10-17 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
|
US4879224A
(en)
*
|
1985-01-10 |
1989-11-07 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
|
WO1986004608A1
(en)
*
|
1985-02-05 |
1986-08-14 |
Synergen Biologicals, Inc. |
Metalloproteinase inhibitor sequence recombinant vector system for using same and recombinant-dna method for the manufacture of same
|
JPS61185189A
(ja)
*
|
1985-02-08 |
1986-08-18 |
Green Cross Corp:The |
新規インタ−フエロン−α↓1DNA配列、組み換えプラスミド及び形質転換体
|
US4894332A
(en)
*
|
1985-03-27 |
1990-01-16 |
Biogen, Inc. |
DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins
|
US6774283B1
(en)
|
1985-07-29 |
2004-08-10 |
Calgene Llc |
Molecular farming
|
US4956282A
(en)
*
|
1985-07-29 |
1990-09-11 |
Calgene, Inc. |
Mammalian peptide expression in plant cells
|
DK402785D0
(da)
*
|
1985-09-03 |
1985-09-03 |
Syn Tek Ab |
Fremgangsmaade til fremstilling af et enzym
|
US5248603A
(en)
*
|
1985-09-03 |
1993-09-28 |
Symbicom Aktiebolag |
Superoxide dismutase
|
US4882279A
(en)
*
|
1985-10-25 |
1989-11-21 |
Phillips Petroleum Company |
Site selective genomic modification of yeast of the genus pichia
|
US5135868A
(en)
*
|
1985-10-25 |
1992-08-04 |
Phillips Petroleum Company |
Cultures of yeast of the genus Pichia altered by site selective genomic modification
|
US5028422A
(en)
*
|
1986-05-27 |
1991-07-02 |
Schering Corporation |
Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
|
US5089406A
(en)
*
|
1987-01-07 |
1992-02-18 |
Allied-Signal Inc. |
Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
|
AU623589B2
(en)
*
|
1987-03-02 |
1992-05-21 |
Bristol-Myers Squibb Company |
Platelet related growth regulator
|
JPS6463395A
(en)
|
1987-05-04 |
1989-03-09 |
Oncogen |
Oncostatin m and novel composition having antitumor activity
|
US4961969A
(en)
*
|
1987-05-11 |
1990-10-09 |
Cetus Corporation |
Process for recovering microbially produced interferon-β
|
US5328988A
(en)
*
|
1987-10-26 |
1994-07-12 |
Immunex Corporation |
Interleukin-7
|
US5714585A
(en)
*
|
1987-10-26 |
1998-02-03 |
Sterling Winthrop, Inc. |
Antibodies that are immunoreactive with interleukin-7
|
ES2096556T3
(es)
*
|
1988-02-26 |
1997-03-16 |
Biogen Inc |
Secuencias de adn, moleculas de adn recombinante y procedimientos para producir lipocortinas iii, iv, v y vi.
|
US5605815A
(en)
*
|
1988-03-14 |
1997-02-25 |
Yale University |
Nucleic acids encoding and expression of parathyroid hormone-like peptide
|
WO1989009831A1
(en)
*
|
1988-04-15 |
1989-10-19 |
Research Corporation Technologies, Inc. |
Lak cell cytotoxin
|
DK455789D0
(da)
*
|
1989-09-15 |
1989-09-15 |
Symbicom Ab |
Polypeptid
|
JP2772062B2
(ja)
*
|
1989-09-26 |
1998-07-02 |
株式会社ニッコー |
走行玩具の方向変換装置
|
US5256568A
(en)
*
|
1990-02-12 |
1993-10-26 |
Regeneron Phamaceuticals, Inc. |
Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
|
EP0527771A4
(en)
*
|
1990-04-02 |
1993-05-05 |
Synergen, Inc. |
Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
CA2129533A1
(en)
*
|
1992-02-10 |
1993-08-19 |
Douglas Testa |
Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
|
US5676942A
(en)
*
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
US5912015A
(en)
*
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5711968A
(en)
*
|
1994-07-25 |
1998-01-27 |
Alkermes Controlled Therapeutics, Inc. |
Composition and method for the controlled release of metal cation-stabilized interferon
|
US6869925B1
(en)
*
|
1992-09-09 |
2005-03-22 |
Amgen Inc. |
Inhibition of retrovirus infection
|
JP2649317B2
(ja)
*
|
1993-10-25 |
1997-09-03 |
株式会社キジマ |
手袋の製造方法
|
US6017880A
(en)
*
|
1994-03-09 |
2000-01-25 |
Amgen Inc. |
Inhibition of retrovirus infection
|
SG119177A1
(en)
*
|
1994-12-09 |
2006-02-28 |
Imp College Innovations Ltd |
Identification of genes
|
US6387365B1
(en)
|
1995-05-19 |
2002-05-14 |
Schering Corporation |
Combination therapy for chronic hepatitis C infection
|
EP0850051A2
(en)
*
|
1995-08-31 |
1998-07-01 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
DE69632062T2
(de)
|
1995-11-02 |
2004-11-18 |
Schering Corp. |
Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
GB9712370D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Aepact Ltd |
Therapeutic systems
|
US6472373B1
(en)
|
1997-09-21 |
2002-10-29 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
US6172046B1
(en)
*
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
JP2001523480A
(ja)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
EP1213029A1
(en)
|
1998-05-15 |
2002-06-12 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
JP2002524077A
(ja)
*
|
1998-09-04 |
2002-08-06 |
クリートゲン アクチエンゲゼルシャフト |
抗原キャリヤーとしての弱毒化サルモネラspi2突然変異体
|
PT1894944E
(pt)
|
1998-11-12 |
2010-10-28 |
Schering Corp |
Métodos para a conversão de isoformas de interferão e seus produtos
|
US6281337B1
(en)
|
1998-11-12 |
2001-08-28 |
Schering Corporation |
Methods for conversion of protein isoforms
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
CA2303992A1
(en)
|
1999-04-08 |
2000-10-08 |
Schering Corporation |
Melanoma therapy
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
GB9910812D0
(en)
*
|
1999-05-10 |
1999-07-07 |
Microscience Ltd |
Vaccine composition
|
GB0008419D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Bioinvent Int Ab |
A method for invitro molecular evolution of antibody function
|
CA2405701A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
GB0008966D0
(en)
*
|
2000-04-13 |
2000-05-31 |
Imp College Innovations Ltd |
Vectors for gene therapy
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
EP1377251B1
(en)
*
|
2001-02-20 |
2008-05-28 |
Ortho-McNeil Pharmaceutical, Inc. |
A cell therapy method for the treatment of tumors
|
DK1381384T3
(da)
|
2001-04-24 |
2011-07-25 |
Merck Patent Gmbh |
Kombinationsterapi under anvendelse af anti-angiogene midler og TNFalfa
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
US20080194481A1
(en)
*
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
GB0217033D0
(en)
|
2002-07-23 |
2002-08-28 |
Delta Biotechnology Ltd |
Gene and polypeptide sequences
|
GB0226105D0
(en)
*
|
2002-11-08 |
2002-12-18 |
St Georges S Entpr Ltd |
Pain relief agents
|
GB0304993D0
(en)
*
|
2003-03-05 |
2003-04-09 |
Univ Nottingham Trent |
Novel screening method
|
CA2543789A1
(en)
|
2003-10-23 |
2005-05-06 |
Illumigen Biosciences, Inc. |
Detection of mutations in a gene associated with resistance to viral infection, oas1
|
AU2005203962C1
(en)
*
|
2004-01-05 |
2012-11-08 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
GB0420091D0
(en)
*
|
2004-09-10 |
2004-10-13 |
Univ Nottingham Trent |
Medical implant materials
|
US20060193849A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
GB0514661D0
(en)
*
|
2005-07-16 |
2005-08-24 |
Medical Res Council |
Methods
|
ATE461214T1
(de)
|
2005-09-05 |
2010-04-15 |
Immatics Biotechnologies Gmbh |
Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
|
ATE440107T1
(de)
|
2005-09-05 |
2009-09-15 |
Immatics Biotechnologies Gmbh |
Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
GB0519398D0
(en)
*
|
2005-09-23 |
2005-11-02 |
Antisoma Plc |
Biological materials and uses thereof
|
GB0607354D0
(en)
*
|
2006-04-12 |
2006-05-24 |
Bioinvent Int Ab |
Agent, Composition And Method
|
GB0607798D0
(en)
*
|
2006-04-20 |
2006-05-31 |
Alligator Bioscience Ab |
Novel polypeptides and use thereof
|
EP2021791A2
(en)
*
|
2006-05-31 |
2009-02-11 |
Unilever N.V. |
Method of screening for compounds that alter skin and/or hair pigmentation
|
WO2007146038A2
(en)
*
|
2006-06-07 |
2007-12-21 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
HUE025636T2
(en)
|
2007-07-27 |
2016-04-28 |
Immatics Biotechnologies Gmbh |
New immunogenic epitope for immunotherapy
|
KR101290892B1
(ko)
|
2007-07-27 |
2013-07-31 |
이매틱스 바이오테크놀로지스 게엠베하 |
신경 및 뇌 종양에 대한 신규 면역요법
|
US20110117054A1
(en)
|
2007-08-27 |
2011-05-19 |
National University Corporation Nagoya University |
Use of ribavirin in blood coagulation disorder
|
EP2385065A1
(en)
|
2007-11-01 |
2011-11-09 |
Perseid Therapeutics LLC |
Immunosuppressive polypeptides and nucleic acids
|
US20100249373A1
(en)
*
|
2007-11-27 |
2010-09-30 |
Richard Martin Ogborne |
Screening methods
|
DK2105501T3
(da)
|
2008-03-27 |
2015-11-23 |
Immatics Biotechnologies Gmbh |
Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer
|
EP2119726B2
(en)
|
2008-05-14 |
2017-11-29 |
Immatics Biotechnologies GmbH |
Novel and powerful MHC-class II peptides derived from survivin and neurocan
|
US8703153B2
(en)
|
2008-06-16 |
2014-04-22 |
Prokarium Ltd. |
Salmonella vectored vaccines against Chlamydia and methods of use
|
DK2172211T3
(en)
|
2008-10-01 |
2015-02-16 |
Immatics Biotechnologies Gmbh |
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
|
EP2348848A4
(en)
*
|
2008-10-03 |
2012-03-07 |
Charlotte Mecklenburg Hospital |
METHOD FOR TREATING HEPATITIS C INFECTION WITH METALOPORPHYRINES
|
ES2342529B1
(es)
|
2008-10-07 |
2011-05-11 |
Proyecto De Biomedicina Cima, S.L. |
Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
|
MX2011006762A
(es)
|
2008-12-23 |
2011-07-20 |
Schering Corp |
Purificacion de interferon recombinantemente producido.
|
GB0905790D0
(en)
|
2009-04-03 |
2009-05-20 |
Alligator Bioscience Ab |
Novel polypeptides and use thereof
|
EP2389362B1
(en)
|
2009-01-21 |
2019-12-11 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010110503A1
(ko)
|
2009-03-27 |
2010-09-30 |
주식회사 중외제약 |
인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
|
US20120128670A1
(en)
|
2009-07-31 |
2012-05-24 |
OSI Pharmaceuticals, LLC |
mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
WO2011046221A1
(ja)
*
|
2009-10-16 |
2011-04-21 |
学校法人立命館 |
インターフェロン-αモジュレーター
|
BR112012010110A2
(pt)
|
2009-10-30 |
2019-09-24 |
Boehringer Ingelheim Int |
regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
|
EP2513146B1
(en)
|
2009-12-18 |
2017-05-03 |
Kancera AB |
Antibodies against ror1 capable of inducing cell death of cll
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
WO2011106105A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
WO2011109572A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
GB201019331D0
(en)
|
2010-03-19 |
2010-12-29 |
Immatics Biotechnologies Gmbh |
Methods for the diagnosis and treatment of cancer based on AVL9
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
WO2011131697A1
(en)
|
2010-04-19 |
2011-10-27 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
IN2012MN02896A
(ja)
|
2010-06-24 |
2015-06-12 |
Panmed Ltd |
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
AU2011284688B2
(en)
|
2010-07-29 |
2015-07-16 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
US20140163041A1
(en)
|
2011-02-08 |
2014-06-12 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
EP3981395A1
(en)
|
2011-02-08 |
2022-04-13 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
GB2490655A
(en)
|
2011-04-28 |
2012-11-14 |
Univ Aston |
Modulators of tissue transglutaminase
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
UA116765C2
(uk)
|
2011-10-20 |
2018-05-10 |
Орізон Джіномікс, С.А. |
(гетеро)арилциклопропіламіни як інгібітори lsd1
|
CN107266345B
(zh)
|
2011-10-20 |
2021-08-17 |
奥瑞泽恩基因组学股份有限公司 |
作为lsd1抑制剂的(杂)芳基环丙胺化合物
|
EP2776024A1
(en)
|
2011-10-31 |
2014-09-17 |
Gilead Pharmasset LLC |
Methods and compositions for treating hepatitis c virus
|
EP3777867A1
(en)
|
2011-11-29 |
2021-02-17 |
Gilead Pharmasset LLC |
Composition and methods for treating hepatitis c virus
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
GB201219678D0
(en)
|
2012-11-01 |
2012-12-12 |
Benf Ab |
Ketone body inhibitors and uses thereof
|
US9624527B2
(en)
|
2013-03-01 |
2017-04-18 |
Boehringer Ingelheim Vetmedica, Inc. |
Quantification of vaccine compositions
|
US20140357595A1
(en)
|
2013-06-04 |
2014-12-04 |
Gilead Pharmasset Llc |
Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
|
TWI819228B
(zh)
|
2013-08-05 |
2023-10-21 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(八)
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
PT3126528T
(pt)
|
2014-04-04 |
2021-09-09 |
Crown Bioscience Inc Taicang |
Métodos para determinar a responsividade a inibidores de mek/erk
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
PE20230321A1
(es)
|
2015-07-01 |
2023-02-22 |
Immatics Biotechnologies Gmbh |
Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
|
CN107912043B
(zh)
|
2015-07-06 |
2022-02-18 |
伊玛提克斯生物技术有限公司 |
用于食管癌和其他癌症免疫治疗的新型肽和肽组合物
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
IL302705A
(en)
|
2016-03-01 |
2023-07-01 |
Immatics Biotechnologies Gmbh |
Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
|
LT3430037T
(lt)
|
2016-03-16 |
2022-12-12 |
Immatics Biotechnologies Gmbh |
Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
|
CN116731156A
(zh)
|
2016-03-16 |
2023-09-12 |
伊玛提克斯生物技术有限公司 |
用于癌症免疫治疗的转染t细胞和t细胞受体
|
MX2018012152A
(es)
|
2016-04-06 |
2019-02-07 |
Immatics Biotechnologies Gmbh |
Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (aml) y otros tipos de cancer.
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
WO2018138257A1
(en)
|
2017-01-27 |
2018-08-02 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
MX2019012225A
(es)
|
2017-04-10 |
2019-12-09 |
Immatics Biotechnologies Gmbh |
Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer.
|
WO2018189152A2
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
US11427614B2
(en)
|
2017-04-10 |
2022-08-30 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
SG11201913302SA
(en)
|
2017-07-07 |
2020-01-30 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
|
US10800823B2
(en)
|
2017-07-07 |
2020-10-13 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|